This article**: Times Business School Author: Wentong.
Recently, Changfeng Pharmaceutical Co., Ltd. ***hereinafter referred to as "Changfeng Pharmaceutical") has successfully passed this round of national medical insurance negotiations and successfully entered the 2023 version of the national medical insurance catalog.
According to public information, Philip Philip (azistine fluticasone nasal spray) is the first nasal glucocorticoid-antihistamine combination preparation in China, suitable for patients with moderate to severe allergic rhinitis aged 12 years and above, with four advantages: stronger efficacy, better safety, better compliance, and unique rose fragrance, which can provide two first-line drugs in one spray, which fundamentally improves the compliance and efficacy of patients.
In line with the original intention of striving for excellence, filling the gap in the field of allergic rhinitis, and benefiting the majority of patients, Changfeng Pharmaceutical has carried out the phase III clinical trial of Shu Feimin in China with a scientific and rigorous attitude, and was approved for marketing in China in November 2022, ending the long-term history of no hormone-antihistamine combination nasal spray in the field of allergic rhinitis in China, and bringing good news to the majority of patients suffering from allergic rhinitis. In the more than one year since its listing, Changfeng Pharmaceutical has carried out a number of post-marketing clinical studies around the clinical application scenarios of Shu Fei Min, further enriching the real-world data of Shu Fei Min, so as to provide help for more patients with allergic rhinitis.
In recent years, with the acceleration of urbanization, air pollution continues to worsen, the incidence of allergic rhinitis has increased year by year, according to the official statistics of WAO (World Response Organization), 10%-30% of ** and 40% of children worldwide suffer from allergic rhinitis. According to China's epidemiological survey, there are about 100 million new patients with allergic rhinitis in China in 6 years, and the prevalence of allergic rhinitis is as high as 176%。According to the statistics of the seventh national population census, the number of allergic rhinitis patients in China is nearly 248.5 billion people, of which about 1 have moderate to severe persistent allergic rhinitis3.2 billion, a huge patient population.
The Chinese Guidelines for the Diagnosis and Development of Allergic Rhinitis (2022, Revised Edition) require that allergic rhinitis should follow the principle of "combination of prevention and treatment, four-in-one", namely: environmental control, drugs, immunization, and health education. Medications** are a key part of controlling the symptoms of allergic rhinitis. Nasal administration has the advantages of high local concentration, rapid onset of action, and lower systemic risk compared with oral administration. After years of clinical use, nasal hormones and nasal antihistamines have become the first-line drugs and the most common drugs recommended by domestic and foreign guidelines for allergic rhinitis.
Azestine hydrochloride and fluticasone propionate, as commonly used nasal antihistamines and nasal glucocorticoids, have outstanding efficacy advantages when used in combination for moderate to severe allergic rhinitis. The ARIA guidelines state that when allergic rhinitis symptoms are not well controlled, a combination of medications** is necessary. However, in clinical practice, the combination of multiple drugs and relatively complex regimens are easy to cause poor medication compliance among patients, affecting the best effect, using two nasal sprays, requiring a certain interval time, and drug dripping will occur when used at the same time, which may cause a decline in patients' medication compliance, thereby reducing the effectiveness of drugs.
With the continuous improvement of residents' income level and health awareness, the demand for nasal spray in terms of ease of use and convenience has gradually emerged. Alistine fluticasone nasal spray provides two first-line medications in a single spray, improving ease of use and patient compliance, while a large body of evidence-based medical evidence suggests that azistine fluticasone nasal spray is more effective in relieving symptoms, improving overall efficacy, and has a good safety profile. After one year of clinical application, Shu Feimin has provided help for the majority of allergic rhinitis patients in China, and has been widely praised by clinicians and patients. Shu Feimin can not only control the symptoms of allergic rhinitis, improve the overall efficacy, but also solve the problem of poor clinical compliance with patients, and is reshaping the pattern of China's allergic rhinitis market.
The entry of Shu Feimin into the national medical insurance will help improve the accessibility of domestic drugs, reduce the burden of allergic rhinitis patients in China, provide clinicians with a new choice, is a new breakthrough in the field of allergic rhinitis, and serve more and broader domestic patients suffering from allergic rhinitis, escorting their nasal health and quality of life.